Silverarc Capital Management, LLC Altimmune, Inc. Transaction History

Silverarc Capital Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $321,000 - $1.74 Million	150,000 New	150,000 $1.69 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $436,327 - $821,233	-49,923 Reduced 49.69%	50,546 $831,000
Q3 2022 Oct 28, 2022	BUY	$10.67 - $22.41 $1.07 Million - $2.25 Million	100,469 New	100,469 $1.28 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $359M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.